National Comprehensive Cancer Network Appoints Dr. Nancy L. Lewis as New Chief Scientific Officer

Dr. Nancy L. Lewis joins the National Comprehensive Cancer Network as CSO to lead clinical guidelines and oncology research programs starting May 2026.

By: AXL Media

Published: Apr 9, 2026, 9:32 AM EDT

Source: Information for this report was sourced from EurekAlert!

A Strategic Leadership Transition in Oncology Research

The National Comprehensive Cancer Network (NCCN) has officially selected Nancy L. Lewis, MD, MBS, FACP, to serve as its next Chief Scientific Officer. This appointment marks a significant transition for the non-profit alliance of leading cancer centers, as Dr. Lewis steps into a role previously held by the organization’s current CEO, Dr. Crystal S. Denlinger. Tasked with steering the NCCN’s scientific vision, Dr. Lewis will be responsible for fostering innovation and discovery during what leadership describes as a pivotal era for global cancer research.

Academic Excellence and Pharmaceutical Expertise

Dr. Lewis enters the role with a deep background in treating both solid tumors and hematologic malignancies. Her professional trajectory includes a recent tenure as the Senior Clinical Program Leader at Novartis Pharmaceuticals, complemented by years spent as an Associate Professor at several high-profile academic cancer centers. Her educational foundation is built on degrees from Penn State University, Temple University School of Medicine, and Rutgers University, followed by a residency at the University of Rochester. Notably, she completed her fellowship at Fox Chase Cancer Center, which is a founding member institution of the NCCN.

Expanding the Scope of Clinical Guidelines

In her capacity as CSO, Dr. Lewis will provide critical oversight for the NCCN Oncology Research Program and the NCCN Clinical Practice Guidelines in Oncology. These guidelines are widely regarded as the gold standard for clinical direction and policy in cancer management. Her responsibilities extend to specialized resources, including the Biomarkers Compendium, the Radiation Therapy Compendium, and the Imaging Appropriate Use Criteria. By managing these technical frameworks, Dr. Lewis will ensure that treatment recommendations remain evidence-based and reflect the latest advancements in oncological science.